*Injection-site reactions include multiple adverse reactions–related terms, such as injection-site pain, induration, and erythema.
The safety of AJOVY was evaluated in two phase 3 clinical trials1
- Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration1
- AJOVY is fully humanized1
- Humanization is a process designed to reduce immunogenicity2
- Less than 1% of patients in both phase 3 trials developed antibodies to AJOVY3
≤2% of patients discontinued due to adverse events in both phase 3 trials in the AJOVY and placebo treatment arms3
